Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Xenon ( (XENE) ) has provided an update.
Xenon Pharmaceuticals Inc. announced its inclusion in the Russell 3000® and Russell 2000® Indexes, effective June 27, 2025. This inclusion is part of the annual reconstitution of these indexes, which are widely used by investment managers and institutional investors as benchmarks for investment strategies. Being part of these indexes can enhance Xenon’s visibility and attract potential investors, potentially impacting the company’s market positioning positively.
The most recent analyst rating on (XENE) stock is a Buy with a $63.00 price target. To see the full list of analyst forecasts on Xenon stock, see the XENE Stock Forecast page.
Spark’s Take on XENE Stock
According to Spark, TipRanks’ AI Analyst, XENE is a Neutral.
Xenon’s primary strengths lie in its strong financial position and positive clinical development progress, as highlighted in the earnings call. However, the absence of revenue and profitability, along with technical and valuation concerns, weigh heavily on the overall stock score.
To see Spark’s full report on XENE stock, click here.
More about Xenon
Xenon Pharmaceuticals Inc. is a neuroscience-focused biopharmaceutical company that specializes in discovering, developing, and delivering therapeutics aimed at addressing high unmet medical needs. The company is advancing an ion channel product portfolio, with a focus on conditions such as epilepsy and depression. Their leading product, Azetukalner, is a highly potent, selective Kv7 potassium channel opener in late-stage clinical development.
Average Trading Volume: 1,072,534
Technical Sentiment Signal: Sell
Current Market Cap: $2.44B
Find detailed analytics on XENE stock on TipRanks’ Stock Analysis page.